Back to search

Article

Enhanced Renal Fibrosis Therapy via Smad3 Silencing using Low- Molecular-Weight Chitosan-Modified PLA Nanoparticles

2026-05-20

Abstract excerpt

<title>Abstract</title> <p>Renal fibrosis represents the final common pathway of chronic kidney disease, driven largely by TGF-β/Smad3 signaling. While silencing Smad3 offers therapeutic potential, the clinical application of small interfering RNA (siRNA) is hindered by rapid degradation and poor cellular uptake. To overcome these barriers, we developed a polylactic acid (PLA) nanoparticle system surface-modified...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d1494d40-7cf4-5e95-a8e4-c02dab125e03
DOI
10.21203/rs.3.rs-9522463/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Enhanced Renal Fibrosis Therapy via Smad3 Silencing using Low- Molecular-Weight Chitosan-Modified PLA NanoparticlesDOI 10.21203/rs.3.rs-9522463/v1
Select a neighboring publication to make it the new centre.